Dermatology Times' Sunday Crossword: March 16, 2025

Welcome to Dermatology Times' Sunday Crossword, where dermatology knowledge meets fun! Each week, we curate a selection of words and terms pulled directly from the latest news in the dermatology world. Whether it's breakthrough treatments, new research findings, or emerging trends, this crossword serves as both a challenge and an opportunity to reinforce your expertise in the field.

For more in-depth insights, don't forget to check out our Weekly Roundup, where we break down the most important stories and updates from the past week. And to stay ahead of the curve and prepare for future crosswords, make sure to follow our content throughout the week.

Try out either our interactive crossword or a static/non-interactive version below.

Interactive Crossword

This crossword was created with CrosswordLabs.com.

Static/Non-Interactive Crossword

Across

3. L'Oréal’s recalled product due to benzene concerns

5. Novartis’ treatment (brand name) with flexible dosing for hidradenitis suppurativa

6. This expert (last name) reviewed the evolving role of antibiotics, emphasizing antibiotic stewardship at AAD 2025

7. Brand name biologic treatment discussed by Jeff Stark, MD, for psoriasis and HS

9. This organization (abbreviated) hosts its Chicago meeting, "Living Well with Eczema" this week

Down

1. Investigational non-invasive therapy for BCC with promising interim results

2. Karan Lal, DO, addressed its complications and safety at AAD 2025

3. This company’s newly-launched "Derm Difference" campaign celebrates dermatologists

4. Biomarker potentially linking diet to acne severity, per recent analysis

8. Surgical technique outperforming wide local excision in SCC control rates

For answers to this week's puzzle, check out next week's edition of the Dermatology Times Sunday Crossword.

Answers from our March 11, 2025 (AAD Insights Edition) puzzle: [Across: 3 - portwine; 4 - tapinarof; 5 - ruxolitinib; 6 - bimekizumab; 8 - baricitinib; 9 - psoriasis; Down: 1 - vilobelimab; 2 - icotrokinra; 7 - lebrikizumab]